House holds hearing on 340B Drug Pricing Program

AHA News Now

The House Energy & Commerce Subcommittee on Oversight and Investigations today held a hearing to review the Health Resources and Services Administration’s oversight of the 340B Drug Pricing Program and how the program impacts patients, providers, manufacturers and other stakeholders. In comments submitted... read more

Topic: Advocacy and Public Policy
Tags: 340B, Drug Pricing Program

CMS releases 2018 outpatient PPS and physician payment proposed rules

AHA News

The AHA July 13 criticized proposed deep cuts to how much the Centers for Medicare & Medicaid Services reimburses hospitals for drugs acquired under the 340B Drug Pricing Program and proposes changes to site-neutral payment policies under Section 603 of the 2015 Bipartisan Budget Act. The provisions are... read more

Topics: Quality and Patient Safety, Advocacy and Public Policy
Tags: 340B, site neutral payment, Drug Pricing Program, Medicare, regulation

CMS releases 2018 OPPS/ASC proposed rule

AHA News Now

The Centers for Medicare & Medicaid Services today proposed to update hospital outpatient prospective payment system rates by 1.75% in calendar year 2018 compared to CY 2017. The rule also would drastically cut Medicare payment for drugs that are acquired under the 340B Drug Pricing Program. Specifically,... read more

Topic: Advocacy and Public Policy
Tags: 340B, quality, physicians, site neutral payment, Medicare, rural, Critical Access Hospitals, regulation, drug prices

Bill would expand 340B discounts for orphan drugs

AHA News Now

Reps. Peter Welch (D-VT) and Gregg Harper (R-MS) yesterday introduced the Closing Loopholes for Orphan Drugs Act (H.R. 2889, legislation that would limit the “orphan drug” exclusion for 340B Drug Pricing Program rural and cancer hospitals. Specifically, the legislation would allow 340B critical access... read more

Topic: Advocacy and Public Policy
Tags: 340B, rural, Critical Access Hospitals

HRSA delays until Oct. 1 the effective date of final rule on 340B drug ceiling prices

AHA News Now

The Health Resources and Services Administration today delayed to Oct. 1 the effective date of its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers. The final rule was subject to multiple delays since January. “The additional time provided to the public before the rule... read more

Topic: Advocacy and Public Policy
Tags: 340B, regulation, drug prices

MedPAC finalizes recommendations for Part B drug payment policy

AHA News Now

The Medicare Payment Advisory Commission yesterday finalized a package of recommendations for Congress aimed at reducing the rapid growth in Part B drug spending. The proposals would require all Part B drug manufacturers to submit Average Sales Price data; reduce Wholesale Acquisition Cost-based payment... read more

Topic: Advocacy and Public Policy
Tag: 340B

HRSA further delays effective date of final rule on 340B drug ceiling prices

AHA News Now

The Health Resources and Services Administration today delayed to May 22 the effective date of its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers, and invited comments on whether a delay to Oct. 1 would be more appropriate. The rule was set to take effect March 21... read more

Topic: Advocacy and Public Policy
Tags: 340B, Drug Pricing Program, regulation, drug prices

AHA Stat blog: Congress should protect the 340B program

AHA News Now

“Congress should preserve the 340B Drug Pricing Program and protect patients and communities,” writes AHA Executive Vice President Tom Nickels in an AHA Stat blog post. He notes, “Every day, we see stories about the exorbitant costs of prescription drugs and the serious challenges they pose for... read more

Topic: Advocacy and Public Policy
Tags: 340B, Drug Pricing Program, drug prices

Preserve the 340B program

Blog

Every day, we see stories about the exorbitant costs of prescription drugs and the serious challenges they pose for individuals and the entire health care system.

One program that has a 25-year track record of improving access to medications and health care services for people in vulnerable communities... read more

Topic: Advocacy and Public Policy
Tag: 340B

HRSA delays effective date of final rule on 340B drug ceiling prices to March 21

AHA News Now

The Health Resources and Services Administration today delayed, in accordance with a recent White House memorandum, the effective date of its final rule on drug ceiling prices and civil monetary penalties for manufacturers in the 340B Drug Pricing Program from March 6 to March 21. “The temporary delay in... read more

Topic: Advocacy and Public Policy
Tags: 340B, regulation

Keyword Search

Date